Aura Biosciences (NASDAQ:AURA) Releases Earnings Results, Misses Estimates By $0.10 EPS

11 May 2026, 18:46 by Amy Steele · The Cerbat Gem

Aura Biosciences (NASDAQ:AURA – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10), FiscalAI reports.

Aura Biosciences Stock Down 2.5%

NASDAQ AURA traded down $0.21 on Monday, reaching $8.19. The company had a trading volume of 332,273 shares, compared to its average volume of 349,801. The firm’s 50 day moving average price is $6.66 and its 200 day moving average price is $6.05. Aura Biosciences has a 12 month low of $4.34 and a 12 month high of $9.53. The stock has a market capitalization of $525.80 million, a PE ratio of -4.58 and a beta of 0.37.

Analysts Set New Price Targets

Several analysts have issued reports on AURA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Aura Biosciences in a research report on Friday, March 27th. HC Wainwright increased their price target on shares of Aura Biosciences from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Aura Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $21.50.

Read Our Latest Report on Aura Biosciences

Insider Transactions at Aura Biosciences

In related news, insider Los Pinos Elisabet De sold 47,648 shares of Aura Biosciences stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total transaction of $241,098.88. Following the completion of the transaction, the insider directly owned 409,815 shares of the company’s stock, valued at approximately $2,073,663.90. The trade was a 10.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Amy Elazzouzi sold 8,549 shares of Aura Biosciences stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $5.06, for a total transaction of $43,257.94. Following the transaction, the senior vice president directly owned 75,532 shares of the company’s stock, valued at approximately $382,191.92. This represents a 10.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 7,039,175 shares of company stock worth $39,656,217. 6.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC increased its stake in shares of Aura Biosciences by 49.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after acquiring an additional 2,104 shares during the period. Water Island Capital LLC purchased a new position in Aura Biosciences during the third quarter valued at $64,000. Invesco Ltd. acquired a new stake in shares of Aura Biosciences in the second quarter valued at about $76,000. BNP Paribas Financial Markets raised its position in shares of Aura Biosciences by 286.6% in the second quarter. BNP Paribas Financial Markets now owns 13,499 shares of the company’s stock valued at $85,000 after buying an additional 10,007 shares during the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in Aura Biosciences during the second quarter worth about $102,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

(Get Free Report)

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.